1 unchanged sentence
Market Information
−Removed: Our common stock is listed on the Nasdaq Stock Market LLC under the symbol “TRVI.” Trading of our common stock commenced on May 7, 2019 in connection with our initial public offering, or IPO.
−Removed: Prior to that time, there was no established public trading market for our common stock.
+Added: Our common stock is listed on the Nasdaq Stock Market LLC under the symbol “TRVI.”
As of March 17, 2022, there were approximately 19 holders of record of our common stock.
3 unchanged sentences
We currently intend to retain all available funds and any future earnings to finance the operation, development and growth of our business.
−Removed: In addition, the terms of any future debt or other financing that we may obtain may also preclude us from declaring or paying dividends on our common stock.
+Added: In addition, the terms of the SVB Term Loan preclude us from paying dividends and the terms of any future debt or other financing that we may obtain may also preclude us from declaring or paying dividends on our common stock.
Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.
4 unchanged sentences
The aggregate gross proceeds to us from our IPO offering were $55.0 million.
−Removed: All of the shares of stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No.
+Added: All the shares of stock issued and sold in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1 (Registration No.
333-230745), which was declared effective by the SEC on May 7, 2019.
1 unchanged sentence
No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning 10% or more of any class of our equity securities or to any other affiliates.
−Removed: As of December 31, 2020, we used approximately $19.9 million of the net proceeds from the IPO to fund the development of Haduvio for the treatment of pruritus associated with prurigo nodularis and the treatment of chronic cough in patients with IPF and for general corporate purposes.
−Removed: There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus for the IPO filed with the SEC pursuant to Rule 424(b) under the Securities Act.
−Removed: We have invested the net proceeds from the IPO in money market funds.
−Removed: Selected Financial Data.
−Removed: Not applicable .
+Added: As of December 31, 2021, we have used all of the net proceeds from the IPO to fund the development of Haduvio for the treatment of pruritus associated with prurigo nodularis and the treatment of chronic cough in patients with IPF and for general corporate purposes.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.